HIMS: Has the Telehealth Fever Cooled Down?

If you missed the best recent articles:

• 5 Historic Asset Bubbles & Lessons for Investors

• Streaming Wars: Who Is the Winner?

• Druckenmiller - The Investing Legend Who Has Never Lost

• Grab – The Super App Dominating Southeast Asia

• Amazon - Pioneer in the AI Era

• Which Stocks Did the Whales Buy and Sell in Q4?

7 months ago, when Hims&Hers (HIMS) was still hovering around 16 USD, Viet Hustler had a detailed analysis article on the potential of this telehealth company. Not long after, HIMS accelerated and hit a peak of 68.7 USD on 02/19/2025 — recording 430% growth in just a few months, making many investors confident in a bright future.

However, the Q4 FY24 financial report created an unexpected turning point:

• Gross margin decline raising concerns about HIMS's financial health.

• Over-reliance on GLP-1 weight loss drugs leading the market to suspect that the company is betting too much on a “star” product without a revenue diversification strategy.

As a result, HIMS stock price has dropped up to 50% from the peak, wiping out most of the previous accumulated gains.

However, are HIMS's business results and future prospects as bad as the market is pricing?

Today, Viet Hustler will update with readers the latest situation of HIMS as well as evaluate the company's challenges and opportunities in the future.

• HIMS is in a good position to grow

• Q4 FY24 Business Results

• HIMS's Future Development Prospects

• Risks of Investing in HIMS